Scott Arthur MP: speeches

Speeches

• 1 Sept 2026 · Direction of Government · Hansard source

  More

  I thank the Prime Minister for his statement. He mentioned the triple-helix model, but what is missing from that model in Scotland is that local authorities are not empowered to play their part. On Friday, Liz McAreavey from the Edinburgh chamber of commerce and the chief executive of the Glasgow chamber of commerce wrote to the Prime Minister asking that he works with the First Minister in Scotland and city region leaders right across the Edinburgh-Glasgow region to forge a devolution deal that enables these cities to meet their full potential. Will he take that offer seriously?

• 9 Jul 2026 · Lobular Breast Cancer: Moon Shot Project · Hansard source

  More

  I appreciate that the Minister is substituting for another excellent Minister, my hon. Friend the Member for Washington and Gateshead South (Mrs Hodgson); I am sad that she is not here, because she is fantastic. We ringfence money for brain tumour research—I know that that community wants more money, so I am not saying it is the gold standard, but we have made that choice, because we recognised the public concern about brain tumours. There is also public concern about lobular breast cancer and the feeling that people who have it are being left behind. It is fantastic that we have better screening coming on board, but ultimately people need treatment if they are diagnosed during the screening process. The Minister highlighted the fact that there is a competitive bidding process. Is it the case that the bids are not good enough? If that is the case, can we invest money to improve the quality of those bids? As I said earlier, we could bring in better staff, perhaps from overseas, or invest in PhD students to work in this area.

• 9 Jul 2026 · Lobular Breast Cancer: Moon Shot Project · Hansard source

  More

  Exactly. In a former life, I was an academic. UKRI does at times engage with academics to fine-tune such questions. UKRI provides funding to universities, if needed, to bring the very best people to the UK either temporarily or on longer-term contracts to help to make a difference in the UK. Those things are perhaps all part of the solution. My hon. Friend is absolutely right. I am grateful for the opportunity to support this vital debate. It shines much-needed light on a disease that is still under-resourced, as has been said, and it honours the legacy of a woman who dedicated her final years to fighting it: the late Susan Michaelis. I was not fortunate enough to meet her but, as a result of the excellent introduction of the hon. Member for Horsham, I feel I know a little bit about her and her character. I am grateful for that introduction. Lobular breast cancer, despite being the second most common form of breast cancer, has historically received a mere 1% of breast cancer research funding. Susan refused to accept that disparity and the Lobular Moon Shot Project is her legacy—but it has to be more than a project. Hopefully, progress will be her real legacy. The project demands better treatment for every woman who receives a lobular breast cancer diagnosis. That is why all of us are in the Chamber for this debate. I recently received an incredibly powerful letter from a leading oncologist, Dr Michie. She is based in Edinburgh, treats patients in Scotland and works closely with the community of those with lobular breast cancer. She expressed deep professional frustration on behalf of her patients, explicitly stating that lobular breast cancer has been neglected for too long. People who meet patients day in, day out and week in, week out still have a real frustration about the lack of progress. Dr Michie’s letter also highlighted the fact that lobular breast cancer is different from the more common ductal types of breast cancer, with an entirely unique tumour biology, different responses to drug treatments, and distinct and highly challenging patterns of spread. The different response to drug treatments is really important because, in the absence of proper treatments, women are often faced with a drug that was not actually designed for the condition that they have. Yet clinical trials rarely even present separate response data for lobular cases: today a grand total of zero lobular-specific clinical trials are actively recruiting patients in the UK. That should shame us, based on what we have discussed already in this debate, and on the scale and breadth of the campaign that has been run. Additionally, the incidence of lobular breast cancer is rising rapidly, climbing by nearly 3% annually. Because it does not form the typical lump, it is notoriously difficult to detect using classical imaging. That is 3% annual growth in diagnoses of this condition—I know that, as a Government, we are really keen on growth but not that kind. To fix it, we need to improve our pre-clinical understanding of how and why the disease spreads. I believe that the work package plan of the Lobular Moon Shot Project is precisely the kind of ambitious and collaborative plan that can help us to improve patient outcomes across the board. If people do not believe that, let us have a conversation about how it can be improved.